Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCUE-HUB
2023-510504-45-00Phase 2Authorised
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic fecal microbiota, atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Incidence of grade >3 adverse events and Disease control rate at 12 weeks after fecal microbiota transplantation. Planned start May 2026; status: authorised.
02
Drugs
allogeneic fecal microbiotaatezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-510504-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510504-45-00.